Moreover, the armamentarium of treatments for PCa has increased in recent years thanks to the FDA/EMA approval of new AR pathway inhibitors (ARPIs) such as abiraterone acetate [10,11,12], an irreversible inhibitor of the cytochrome P450 17α−hydroxy/17,20-lyase (CYP17) enzyme responsible for androgen synthesis, and next-generation anti-androgens such as enzalutamide [13,14,15,16], apalutamide [17,18], and darolutamide [19], which have changed the therapeutic landscape of PCa at different stages of the disease. Here, CYP17A1 is linked to posterior cortical atrophy.